A B S T R A C T Addition of increasing amounts of JIlabeled desialylated thyroxine-binding globulin (DTBG) ceruloplasmin.
INTRODUCTION
The presence of carbohydrate chains attached to many of the serum proteins has long been recognized. Nevertheless, the biologic significance of these sugar moieties has remained obscure. Ashwell and his colleagues have postulated that sialic acid-a nine carbon acidic monosaccharide which occurs only in the terminal position of glycoprotein carbohydrate side chains-appears to play a key role in determining the circulating life of serum glycoproteins (1) (2) (3) . They have presented evidence that exposure of the penultimate galactosyl moiety of glycoprotein carbohydrate side chains by removal of the terminal sialic acid groups results in rapid clearance of many serum glycoproteins from the circulation and that the glycoproteins thus cleared can be recovered in the liver (1) (2) (3) . This phenomenon has been demonstrated for orosomucoid, fetuin, haptoglobin, a2-macroglobulin, ceruloplasmin, human chorionic gonadotropin and follicular stimulating hormone (2) . These observations have been extended by their demonstration that isolated hepatic cell plasma membranes contain specific saturable binding sites for the desialylated glvcoproteins (4) .
Pathologic processes in the liver are often accompanied by changes in serum glycoproteins. Diffuse parenchymal liver disease usually presents with decreased serum al-bumin and polyclonal increase in serum gammna globulin (5) . Increased ai-antitrypsin levels may contribute to the apparent rise in gamma globulin seen wvith electrophoresis (6) . Beta globulin is often increased in primary biliary cirrhosis (7) and a2-macroglobulin may rise in inflammatory exacerbations (8) .
Observations made in this laboratory have shown that serum of cirrhotic patients often contains an additional thyroxin (T4 )'-binding protein which has an electrophoretic mobility slower than that of the glycoprotein thyroxine-binding globulin (TBG) (9) . Other evidence previously reported has suggested that this slowly moving T4-binding protein represents a partially desialylated form of TBG. At that time we proposed that hepatocellular destruction with fibrotic replacement of liver tissue might impair the clearance of desialylated glycoproteins from the circulation (9) .
We now present evidence that human TBG can be added to the list of serum glycoproteins which bind to hepatic cell plasma membranes upon desialylation. We also show that desialylated TBG can be used in a hepatic cell plasma membrane inhibition assay as developed by Van Lenten and Ashwell (4) to demonstrate levels of circulating desialylated glycoproteins in normal human serum and markedly increased levels in serums from patients with liver disease. METHODS TBG was purified from pooled serum by affinity chromatography as previously described (10 Rat liver cell plasma membranes were prepared by Ray's modification (13) of a method reported by Neville (14) 1 Abbreviations used in this paper: DTBG, desialylated thyroxine-binding globulin; TBG, thyroxine-binding globulin; T4, thyroxine. using differential centrifugation in a discontinuous sucrose gradient. Protein concentrations were determined by the method of Lowry, Rosebrough, Farr, and Randall (15) . Each membrane preparation was assayed by measurement of the marker enzyme, alkaline phosphatase. In our hands membrane preparations contained about four times the activity of this enzyme as those reported by Van Lenten and Ashwell (4) and about 1/3 the activity reported by Ray (13) . The membranes were stored at -60'C until used. Different preparations of membranes demonstrated little variation either in the binding curves or maximum binding capacity for desialylated TBG. The frozen membranes could be used successfully for at least 6 wk.
Binding of desialylated glycoproteins to rat liver cell plasma membranes was carried out as described by Van Lenten and Ashwell (4 , Rutherford, N. J.) and were separated from the red cells within 2 h. All specimens were stored at 4VC and were stable for up to 2 wk when assayed in the inhibition binding assay. Normal serum stored at -20'C for 3 yr showed a twofold increase in the expected inhibitory level. Inhibitory activity in serum was stable after heating to 650C for 30 min.
Column chromatography of normal serum and serum from patients with hepatic cirrhosis was done on Sephadex G-200 using a 1.5 X 100-cm Glenco column (Glenco Scientific, Inc., Houston, Tex.). The gel was equilibrated with 0.06 M Tris-HCI, pH 8.6, and elution of the serum sample was done with the same buffer. A flow rate of 6 ml/h was used and 1.2-ml aliquots were collected. The optical density at 280 nm was used for determining protein concentration. added, approximately 95% of the counts were bound; when saturation was reached approximately 3% of the added radioactivity was bound. Native (fully sialylated) ['5I]TBG bound to the membranes only negligibly under these conditions (Fig. 1) . As shown by Van Lnten and Ashwell (4), the presence of Ca++ was required for binding in this system (Fig. 2) .
The results of inhibition assays in which purified unlabeled desialylated glycoprotein inhibitors were preincubated with the membranes are shown in Fig. 3 (Fig. 4) . The similarity of the inhibition curves of purified desialylated glycoproteins and whole serum suggested an interaction at the same binding sites on the liver cell membranes. Experiments were performed to measure binding inhibition of mixtures of normal and abnormal serums of known individual inhibitory activity. The total inhibitory activity of the combined serums was always recoverable to within 10% of the values expected from determinations using the individual serums.
Varying the time of membrane preincubation with serum from 60 min to 12 h did not affect the level of inhibition of ["1I] DTBG binding.
In order to examine the possibility that the inhibition of membrane binding of ["I] DTBG by whole serum might be due to a circulatory neuraminidase which might destroy the membrane binding sites or to a circulating galactosidase which might cleave the exposed penultimate galactose from the desialylated ["I]DTBG, thereby preventing membrane binding of the labeled glycoprotein, parallel incubations of membranes in the presence of increasing amounts of serum were performed and the time-course of binding observed. It was expected that if the serum contained factors other than desialylated glycoproteins that interfered with binding, the binding curves might not demonstrate parallelism once maximal inhibition was reached. Fig. 5 shows that the inhibition curves are parallel once maximal binding was reached. (Fig. 9) . The range of inhibitory activity of 10 ul of normal serums was equivalent to 2-10 ng DTBG. Serum from patients with Laennec's cirrhosis showed inhibition equivalent to 30-80 ng DTBG and two cases with biliary cirrhosis showed inhibition equivalent to 22-50 ng DTBG. Two patients with hepatic metastases showed elevated inhibi- When the results of inhibition of [n"I]DTBG binding by serum from patients with a variety of hepatic disease were compared with standard liver function test results in these patients, no simple correlation could be found between serum inhibitory activity and levels of alkaline phosphatase, serum glutamic oxalacetic transaminase, total bilirubin, serum albumin, or serum globulin.
Column chromatography on Sephadex G-200 of a sample of serum from a patient with cirrhosis ( Fig. 10) showed the expected reversal of albumin to globulin ratio compared to normal serum. The amount of inhibitory activity was greater than that of normal serum fractions and the pattern of inhibition was unique in showing three spikes of activity corresponding to the macroglobulins, to globulins with a molecular weight roughly equal to that of albumin, and a small peak of protein more retarded and therefore presumably of lower molecular weight than albumin. This same pattern of optical density and inhibitory activity was observed in three additional patients with end-stage cirrhosis whose serum was fractionated on Sephadex G-200. There did not appear to be any simple relationship between optical density at 280 nm and inhibitory activity. It should also be pointed out that this was not a universal finding in all serums obtained from patients with cirrhosis. Preliminary experiments with G 25 Sephadex column chromatography and ultrafiltration through UM-10 Amicon filters (Amicon Corp., Lexington, Mass.) of the material from the low molecular weight peak suggested a molecular weight of 10,000 or less. Immunoelectrophoresis of this material with rabbit antibody directed against whole human serum failed to produce any precipitin line. The significance of this last peak of inhibitory material is not known and is currently under investigation.
DISCUSSION
When present, sialic acid occurs as the terminal nonreducing sugar of carbohydrate chains of glycoproteins (18) . The penultimate sugar is typically galactose (19) . Morell, Gregoriadis, Scheinberg, Hickman, and Ashwell (2) showed that desialylation and injection of purified ceruloplasmin resulted in the rapid hepatic uptake of the glycoprotein from the circulation and that the integrity of the exposed galactose moiety was an absolute requirement for clearance. Similar results for other serum glycoproteins were shown including orosomucoid, fetuin, thyroglobulin, haptoglobin, a-macroglobulin, human chorionic gonadotropin, and follicle-stimulating hormone (2). In addition, Van Lenten and Ashwell (4) have demonstrated specific saturable binding sites for a number of desialylated glycoproteins on a plasma membrane fraction of rat liver cells. However, the binding process in both the in vivo system, observed by injecting desialylated glycoproteins into the circulation, and the in vitro system, using the membrane binding assay, was followed by using exogenously prepared desialylated glycoproteins. There was no evidence that serum glycoproteins exist in a desialylated form in vivo or that hepatic plasma membrane binding normally plays a role in their turnover. Our finding of a partially desialylated form of TBG in serum from patients with hepatic cirrhosis (9) led us to investigate the possible physiologic significance of hepatocellular desialylated glycoprotein binding.
We have presented evidence that the hormone transport protein, TBG, may now be added to the group of serum glycoproteins which, after desialylation, bind to liver cell membranes. The inhibition curves shown here indicate that desialylated TBG binds to liver cell plasma membranes more avidly than desialylated fetuin or ceruloplasmin, but less strongly than desialylated orosomucoid. Quantitative determination of affinity constants employing Scatchard plots has not been possible because of the failure to demonstrate reversibility of binding under the conditions of the assay. These findings are consistent with our observations that desialylated TBG is rapidly cleared from the circulation by the liver in rats, rabbits, and humans (20) .
We have attempted to demonstrate the presence of desialylated glycoproteins in serum by its ability to compete with the binding of a purified desialylated glycoprotein by the liver plasma membrane preparation. For convenience, we chose TBG. In these studies competitive activity in both normal and cirrhotic serums has been demonstrated. The inhibition of membrane binding of desialylated, TBG by serum suggests that the circulation normally has detectable levels of partially desialylated glycoproteins. Evidence for this includes (a) activity in an inhibition assay previously shown to be quite specific for desialylated glycoproteins and glycopeptides (4), (b) the occurrence of peaks of inhibition throughout the molecular weight range of serum proteins, (c) a similar but enhanced pattern of inhibition after column chromatography of serum pretreated with neuraminidase, and (d) the similarity of the inhibition curves of serum and of desialylated purified glycoproteins.
The physiologic significance of hepatocyte plasma membrane binding is suggested by the glycoprotein alterations observed in serum from cirrhotic patients. These serums showed a marked elevation of inhibitory activity which we believe reflects an increase in levels of desialylated glycoproteins. This interpretation is supported by our earlier studies of TBG from patients with cirrhosis (9) which showed the appearance of a partially desialylated form of this protein in some of their serums. An increase in desialylated glycoproteins in serum from patients with hepatic cellular damage could result from several abnormal conditions which may accompany cirrhosis such as: (a) pathologic alteration of hepatocyte function resulting in the synthesis and release of glycoproteins into the circulation with incomplete carbohydrate chains, (b) pathologic decreases in the number of hepatocyte membrane binding sites, (c) desialylation of serum glycoproteins at a rate in excess of uptake by a damaged liver, (d) presence in the serum of substances which may compromise the ability of desialylated glycoproteins to bind to the hepatocyte membranes. These abnormalities, either separately or in combination., could result in an increase in the steady-state level of serum desialylated glycoproteins.
If one assumes that the in vitro inhibition binding assay is a good reflection on the in vivo binding process, then the fourth possibility is considered unlikely because of the following observations. Increasing serum concentrations yield parallel inhibition curves (Figs. 4 (21) (22) (23) . Although gamma globulin may be less susceptible to the in vivo mechanism for desialylation than the majority of glycoproteins, a case report has appeared describing a monoclonal gammopathy in association with cirrhosis in which the IgG was deficient in sialic acid (5) . A specific interaction between the desialylated IgG and IgM was found, suggesting an antibody-antigen complex. Thus, the removal of sialic acid from circulating IgG may "uncover" an antigenic site to which autoantibodies might be produced. Accordingly, the hepatic removal of desialylated glycoproteins from the circulation may not be just a "passive" catabolic process, as suggested by Van den Hamer, Morell, Scheinberg, Hickman, and Ashwell (1) but may protect the organism against production of autoantibodies to "damaged" proteins.
Serum from patients with cirrhosis has also been reported to contain increased levels of a soluble galactosyltransferase (24) . A preliminary report (25) , as yet not confirmed, suggests that the binding site for desialylated glycoproteins on the liver cell is a membrane-bound galactosyltransferase. A soluble receptor site in the serum for desialylated glycoproteins could effectively compete with the hepatic membrane binding sites and result in impaired hepatic uptake. In addition, the increased galactosyltransferase activity in serum of patients with cirrhosis could reflect degradation of liver membrane binding sites. As yet, the mechanism(s) of desialylation of serum glycoproteins is not understood.
The clinical importance of the inhibition assay must await the study of a larger number of patients. However, Laennec's and biliary cirrhosis, primary and metastatic liver carcinoma, and hepatitis appear to be associated with elevated levels of circulating desialylated glycoproteins. Patients with abnormal liver function tests due to congestive heart failure, pancreatitis, or extrinsic biliary tract obstruction had normal inhibitory activity. We are currently engaged in following the time-course of desialylated serum glycoprotein levels of a larger number of patients with a variety of pathologic entities in order to evaluate the clinical value of this test in determining diagnosis and prognosis of hepatic disease.
